Haematologica
October 8, 2026 · via Europe PMC
Five-year survival and infectious complications of donor-derived CD7 CAR-T therapy in T-ALL.
Shan L, Li T, Wang Y, Ling Z, Wang Z, Zhao C, Feng X, Pan J.
AI summary — for doctors, generated from the abstract only
No abstract is available for this study, so its results on donor-derived CD7 CAR-T therapy in T-ALL cannot be summarized.
What was studied
Based only on the title, the work concerns five-year survival and infectious complications after donor-derived CD7 CAR-T therapy in T-cell acute lymphoblastic leukemia; no design or population details are provided.
Key findings
- No abstract was provided, so no results can be reported
Clinical relevance
CAR-T for T-ALL and its infection risk are of interest to hematologists, but this record gives no data to assess.
Who should care
Limitations
No abstract is available, so the design, sample and limitations cannot be assessed and no numbers are stated.
No practical conclusions can be drawn without the underlying data.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
Not available.
DOI
10.3324/haematol.2026.301895
PMID
42845047
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed